Wipaporn Natalie Songtaweesin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wipaporn Natalie Songtaweesin has a total of 188 co-authors. Here are the top co-authors by number of shared publications:
- Thanyawee Puthanakit
Chulalongkorn University
15 shared publications Thanyawee Puthanakit
Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
11 shared publicationsPrissana Wongharn
Center of Excellence for Pediatric Infectious Diseases and Vaccines, Bangkok, Thailand
7 shared publications- Nittaya Phanuphak
Institute of HIV Research and Innovation Bangkok Thailand
6 shared publications - Surinda Kawichai
Center of Excellence for Pediatric Infectious Diseases and Vaccines, Chulalongkorn University, Bangkok, Thailand
6 shared publications - Chutima Saisaengjan
Center of Excellence for Pediatric Infectious Diseases and Vaccines, Faculty of Medicine, Chulalongkorn University
5 shared publications
Latest Publications
- 4 August 2026
- Published by Wolters Kluwer Health in Journal of the Association of Nurses in AIDS Care
Effective Handling of Health Care Transition for Young People Living With HIV: A Consensus of Experts in Thailand Using Modified Delphi Method
The aim of our study was to develop consensus from experts and advocates on the health care transition for young people living with HIV from pediatrics to adult care in Thailand using a modified Delphi method. Participants included physicians (58%), nurses (20%), clinic coordinators (11%), and outreach workers (11%). Survey items were distributed to gather responses. Consensus was achieved after two rounds of surveys (response rates: 86% and 94.5%, respectively). Key priorities identified included (1) pediatric clinics: early transition planning, individualized readiness assessment, and focusing on youth with an increased risk of poor treatment outcomes; (2) transition process: strong pediatric–adult clinic collaboration; (3) health care coverage scheme and system: making sure that youth are familiar with their resources and options; (4) adult clinics: providing communication skills training for providers aimed at offering youth-friendly, nonstigmatizing services; and (5) post-transition follow-up: communication to ensure a warm handoff. Effective transition care for young people living with HIV requires early preparation, sustained interclinic communication, and continuity-supportive care models.
- 4 August 2026
- Published by Wolters Kluwer Health in Journal of the Association of Nurses in AIDS Care
Effective Handling of Health Care Transition for Young People Living With HIV: A Consensus of Experts in Thailand Using Modified Delphi Method
The aim of our study was to develop consensus from experts and advocates on the health care transition for young people living with HIV from pediatrics to adult care in Thailand using a modified Delphi method. Participants included physicians (58%), nurses (20%), clinic coordinators (11%), and outreach workers (11%). Survey items were distributed to gather responses. Consensus was achieved after two rounds of surveys (response rates: 86% and 94.5%, respectively). Key priorities identified included (1) pediatric clinics: early transition planning, individualized readiness assessment, and focusing on youth with an increased risk of poor treatment outcomes; (2) transition process: strong pediatric–adult clinic collaboration; (3) health care coverage scheme and system: making sure that youth are familiar with their resources and options; (4) adult clinics: providing communication skills training for providers aimed at offering youth-friendly, nonstigmatizing services; and (5) post-transition follow-up: communication to ensure a warm handoff. Effective transition care for young people living with HIV requires early preparation, sustained interclinic communication, and continuity-supportive care models.
- Open Access
- 20 May 2026
- Published by Elsevier in The Lancet Regional Health - Southeast Asia
- Vol. 49, 100782
Virologic outcomes on Dolutegravir-based therapy among children and adolescents living with HIV in Thailand: findings from a national registry database
- 20 May 2026
- Published by Elsevier in The Lancet Regional Health - Southeast Asia
- Vol. 49, 100782
Open AccessVirologic outcomes on Dolutegravir-based therapy among children and adolescents living with HIV in Thailand: findings from a national registry database
- Open Access
- 18 July 2025
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 22 (1) , 1-9
Attitudes and eligibility of long-acting cabotegravir/rilpivirine treatment among youth living with HIV in a clinical and national cohort in Thailand: a cross-sectional study
Long-acting cabotegravir/rilpivirine (LA-CAB/RPV) is the only available approved injectable antiretroviral therapy (ART) for youth living with HIV (YLHIV). However, it is not yet available through the Thai National AIDS Program (NAP). This study assessed Thai YLHIV attitudes toward LA-CAB/RPV and identified the proportion of medically eligible YLHIV within the NAP. Two cross-sectional studies were conducted, the first study conducted in an HIV clinic in Bangkok involving YLHIV aged 13–24 years, assessing attitudes via questionnaires. The second study analyzed medical eligibility among 14,670 youth aged 12–24 years in the NAP, defined by current HIV RNA < 50 copies/ml, no prior treatment failure (HIV RNA < 1,000 copies/ml) and no suspected archived resistance to CAB/RPV. Logistic regression was performed to identify factors associated with willingness and eligibility. From April to June 2024, 100 YLHIV (median age 20 years; IQR 19.0-21.7) were enrolled, 71% had non-perinatally acquired HIV (non-PHIV). Overall, 85% expressed willingness to use LA-CAB/RPV. Non-PHIV youth showed significantly higher interest (93.0% vs. 65.5%); OR 6.9 [95% CI: 2.1–22.8], despite a shorter median treatment duration (2.7 vs. 14.3 years). LA-CAB/RPV was considered more convenient than pills by 76%, although 42% anticipated injection-site reactions. Among YLHIV in the NAP (median age 22 years; IQR 20–23), 64% were medically eligible, non-PHIV youth also had a higher eligibility proportion (70% vs. 32%) with an aOR 2.0 [95% CI: 1.7–2.4]. The majority of Thai YLHIV showed positive attitudes towards LA-CAB/RPV, with two-thirds meeting medical eligibility criteria. Enhancing access to generic formulations of this regimen could significantly impact lifelong HIV management.
- 18 July 2025
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 22 (1) , 1-9
Open AccessAttitudes and eligibility of long-acting cabotegravir/rilpivirine treatment among youth living with HIV in a clinical and national cohort in Thailand: a cross-sectional study
Long-acting cabotegravir/rilpivirine (LA-CAB/RPV) is the only available approved injectable antiretroviral therapy (ART) for youth living with HIV (YLHIV). However, it is not yet available through the Thai National AIDS Program (NAP). This study assessed Thai YLHIV attitudes toward LA-CAB/RPV and identified the proportion of medically eligible YLHIV within the NAP. Two cross-sectional studies were conducted, the first study conducted in an HIV clinic in Bangkok involving YLHIV aged 13–24 years, assessing attitudes via questionnaires. The second study analyzed medical eligibility among 14,670 youth aged 12–24 years in the NAP, defined by current HIV RNA < 50 copies/ml, no prior treatment failure (HIV RNA < 1,000 copies/ml) and no suspected archived resistance to CAB/RPV. Logistic regression was performed to identify factors associated with willingness and eligibility. From April to June 2024, 100 YLHIV (median age 20 years; IQR 19.0-21.7) were enrolled, 71% had non-perinatally acquired HIV (non-PHIV). Overall, 85% expressed willingness to use LA-CAB/RPV. Non-PHIV youth showed significantly higher interest (93.0% vs. 65.5%); OR 6.9 [95% CI: 2.1–22.8], despite a shorter median treatment duration (2.7 vs. 14.3 years). LA-CAB/RPV was considered more convenient than pills by 76%, although 42% anticipated injection-site reactions. Among YLHIV in the NAP (median age 22 years; IQR 20–23), 64% were medically eligible, non-PHIV youth also had a higher eligibility proportion (70% vs. 32%) with an aOR 2.0 [95% CI: 1.7–2.4]. The majority of Thai YLHIV showed positive attitudes towards LA-CAB/RPV, with two-thirds meeting medical eligibility criteria. Enhancing access to generic formulations of this regimen could significantly impact lifelong HIV management.
- 10 June 2025
- Published by Taylor & Francis in Future Virology
- Vol. 20 (6-7) , 251-254
Conference proceedings from the 27th Bangkok International Symposium on HIV medicine
- 10 June 2025
- Published by Taylor & Francis in Future Virology
- Vol. 20 (6-7) , 251-254
Conference proceedings from the 27th Bangkok International Symposium on HIV medicine
- 12 March 2025
- Published by Elsevier in The Lancet HIV
- Vol. 12 (4) , e240-e241
Long-acting PrEP for adolescent girls and young women
- 12 March 2025
- Published by Elsevier in The Lancet HIV
- Vol. 12 (4) , e240-e241
Long-acting PrEP for adolescent girls and young women
- Open Access
- 2 March 2025
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 22 (1) , 1-5
Brief communication: attitudes and preferences of long-acting injectable HIV preexposure prophylaxis among Thai adolescents and young adults
This study aimed to explore willingness to use and preference for long-acting injectable PrEP (LAI-PrEP) among Thai youth at risk of HIV. A cross-sectional study was conducted in 100 Thai youth aged 18 to 24 years attending a sexual health clinic in Bangkok, Thailand. Participants received information about oral and LAI-PrEP before completing a questionnaire. Of the 98 participants willing to use pre-exposure prophylaxis, 47 preferred the injectable form. Preference for the injectable form was higher among individuals not currently using oral pre-exposure prophylaxis, affordability and longer injection intervals were key for acceptance of long-acting injectable pre-exposure prophylaxis.
- 2 March 2025
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 22 (1) , 1-5
Open AccessBrief communication: attitudes and preferences of long-acting injectable HIV preexposure prophylaxis among Thai adolescents and young adults
This study aimed to explore willingness to use and preference for long-acting injectable PrEP (LAI-PrEP) among Thai youth at risk of HIV. A cross-sectional study was conducted in 100 Thai youth aged 18 to 24 years attending a sexual health clinic in Bangkok, Thailand. Participants received information about oral and LAI-PrEP before completing a questionnaire. Of the 98 participants willing to use pre-exposure prophylaxis, 47 preferred the injectable form. Preference for the injectable form was higher among individuals not currently using oral pre-exposure prophylaxis, affordability and longer injection intervals were key for acceptance of long-acting injectable pre-exposure prophylaxis.
- 18 December 2024
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 36 (4) , 289-296
High prevalence of hepatitis C virus infection among adolescents and young adults attending HIV and sexual health clinics
Background: The prevalence of hepatitis C virus (HCV) infection among Thai adults is 0.5%–1.0%. This study aims to determine the prevalence of HCV infection among adolescents and young adults (AYA) accessing HIV/sexual health clinics. Methods: A cross-sectional study was conducted among AYA aged 15–24 years attending HIV/sexual health clinics in Bangkok, Thailand. The HCV infection prevalence, defined by anti-HCV antibody positivity using rapid diagnostic tests (SD BIOSENSOR, Korea), were reported with proportions and a 95% confidence interval (CI). Multivariate logistic regression was performed to identify factors associated with HCV infection. Results: From March to August 2023, 300 AYAs with a median age of 21 (interquartile range 20–23) years were enrolled into the study. One-third (29.7%) were people living with HIV (PLHIV). The overall prevalence of HCV infection was 2.7% (95%CI 1.2–5.2). Prevalence was higher among PLHIV (5.6%) compared to AYA without HIV (1.4%) ( p -value 0.053). The factor most significantly associated with HCV infection was people who used drugs (adjusted odds ratio 15.3, 95% CI 2.9–82.0, p -value 0.001). Conclusions: History of drug use was associated with the highest HCV infection prevalence. PLHIV had a trend of higher prevalence. HCV screening in HIV/sexual health clinics is recommended for early detection, treatment, and transmission reduction.
- 18 December 2024
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 36 (4) , 289-296
High prevalence of hepatitis C virus infection among adolescents and young adults attending HIV and sexual health clinics
Background: The prevalence of hepatitis C virus (HCV) infection among Thai adults is 0.5%–1.0%. This study aims to determine the prevalence of HCV infection among adolescents and young adults (AYA) accessing HIV/sexual health clinics. Methods: A cross-sectional study was conducted among AYA aged 15–24 years attending HIV/sexual health clinics in Bangkok, Thailand. The HCV infection prevalence, defined by anti-HCV antibody positivity using rapid diagnostic tests (SD BIOSENSOR, Korea), were reported with proportions and a 95% confidence interval (CI). Multivariate logistic regression was performed to identify factors associated with HCV infection. Results: From March to August 2023, 300 AYAs with a median age of 21 (interquartile range 20–23) years were enrolled into the study. One-third (29.7%) were people living with HIV (PLHIV). The overall prevalence of HCV infection was 2.7% (95%CI 1.2–5.2). Prevalence was higher among PLHIV (5.6%) compared to AYA without HIV (1.4%) ( p -value 0.053). The factor most significantly associated with HCV infection was people who used drugs (adjusted odds ratio 15.3, 95% CI 2.9–82.0, p -value 0.001). Conclusions: History of drug use was associated with the highest HCV infection prevalence. PLHIV had a trend of higher prevalence. HCV screening in HIV/sexual health clinics is recommended for early detection, treatment, and transmission reduction.
- Open Access
- 1 December 2024
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 53, 101248
The urgency of now to end HIV vertical transmission for pregnant and breastfeeding women and their children in Asia and the Pacific
- 1 December 2024
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 53, 101248
Open AccessThe urgency of now to end HIV vertical transmission for pregnant and breastfeeding women and their children in Asia and the Pacific
- Open Access
- 9 October 2024
- Published by Wiley in Journal of the International AIDS Society
- Vol. 27 (10) , e26377
Opportunities for building lifelong resilience and improving mental health for adolescents living with HIV
- 9 October 2024
- Published by Wiley in Journal of the International AIDS Society
- Vol. 27 (10) , e26377
Open AccessOpportunities for building lifelong resilience and improving mental health for adolescents living with HIV
- 16 July 2024
- Published by Wolters Kluwer Health in Current Opinion in HIV and AIDS
- Vol. 19 (6) , 280-286
Challenges towards an AIDS-free generation in Africa and Asia
Purpose of review: To review the latest data on prevention of HIV vertical transmission in Asia and Africa and discuss strategic directions to achieve an AIDS free generation by 2030. Recent findings: Progress in vertical transmission elimination efforts in Africa and Asia have stalled in the last decade, with 130 000 new infections in 2022. Main causes of vertical transmissions vary; in Asia-Pacific due to its low-burden, thus low testing coverage, but high overall vertical transmission rates, in South and East Africa due to new HIV infections during pregnancy and breast/chestfeeding, whereas in Western and Central Africa due to low antiretroviral therapy (ART) coverage. Long-acting injectable ART and neutralizing antibodies for treatment and prevention show promise in supporting efforts to further reduce vertical transmissions. Integrated and more accessible pre- and postnatal care is needed to achieve an AIDS-free generation. Summary: Much can be implemented to address existing HIV service gaps; including strengthening of HIV prevention services for youth and women of childbearing age and pregnant people, early detection and treatment, and the delivery of integrated services that can reach and retain pregnant and postpartum people living with HIV in care.
- 16 July 2024
- Published by Wolters Kluwer Health in Current Opinion in HIV and AIDS
- Vol. 19 (6) , 280-286
Challenges towards an AIDS-free generation in Africa and Asia
Purpose of review: To review the latest data on prevention of HIV vertical transmission in Asia and Africa and discuss strategic directions to achieve an AIDS free generation by 2030. Recent findings: Progress in vertical transmission elimination efforts in Africa and Asia have stalled in the last decade, with 130 000 new infections in 2022. Main causes of vertical transmissions vary; in Asia-Pacific due to its low-burden, thus low testing coverage, but high overall vertical transmission rates, in South and East Africa due to new HIV infections during pregnancy and breast/chestfeeding, whereas in Western and Central Africa due to low antiretroviral therapy (ART) coverage. Long-acting injectable ART and neutralizing antibodies for treatment and prevention show promise in supporting efforts to further reduce vertical transmissions. Integrated and more accessible pre- and postnatal care is needed to achieve an AIDS-free generation. Summary: Much can be implemented to address existing HIV service gaps; including strengthening of HIV prevention services for youth and women of childbearing age and pregnant people, early detection and treatment, and the delivery of integrated services that can reach and retain pregnant and postpartum people living with HIV in care.